Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alnylam Seeks To Advance RNAi Further With Inex Delivery Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

There is an "open invitation" to companies and academia to partner with Inex on RNAi therapies, Inex CEO tells "The Pink Sheet" DAILY.

You may also be interested in...

Alnylam, Nastech Take Different IP Approaches To Pandemic Flu RNAi Therapies

Alnylam predicts companies will come knocking on its door to license its intellectual property in the field.

Alnylam Seeks Deals As RNAi Interest Heats Up

Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.

Inex Plans Complete Spin-Out Into Tekmira In September

Previous spin-out Protiva has filed suit to stop the firm from moving almost all of its assets into a new company.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts